Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2022-08-09 3:11 pm Purchase | 13D | Arcutis Biotherapeutics, Inc. ARQT | Frazier Life Sciences VIII L.P. | 8,745,318 14.6% | 263,411 (+3.11%) | View |
| 2022-02-15 2:18 pm Sale | 13D | Alpine Immune Sciences, Inc. ALPN | Frazier Life Sciences VIII L.P. | 3,164,108 10.8% | -13,734 (-0.43%) | View |
| 2022-01-28 1:39 pm Purchase | 13G | Sierra Oncology Inc. SRRA | Frazier Life Sciences VIII L.P. | 1,264,861 8.4% | 1,062,058 (+523.69%) | View |
| 2021-09-21 3:37 pm Purchase | 13D | Alpine Immune Sciences, Inc. ALPN | Frazier Life Sciences VIII L.P. | 3,177,842 10% | 440,741 (+16.10%) | View |
| 2021-05-12 5:27 pm Sale | 13D | Arcutis Biotherapeutics, Inc. ARQT | Frazier Life Sciences VIII L.P. | 8,481,907 16.9% | -2,084,883 (-19.73%) | View |
| 2021-05-04 12:31 pm Purchase | 13D | Aptinyx Inc. APTX | Frazier Life Sciences VIII L.P. | 3,195,055 4.8% | 4,976 (+0.16%) | View |
| 2021-02-09 11:14 am Purchase | 13D | Arcutis Biotherapeutics, Inc. ARQT | Frazier Life Sciences VIII L.P. | 10,566,790 21.7% | 24,000 (+0.23%) | View |
| 2021-02-04 4:37 pm Sale | 13D | Aptinyx Inc. APTX | Frazier Life Sciences VIII L.P. | 3,190,079 5.1% | -50,037 (-1.54%) | View |
| 2020-10-06 2:42 pm Unchanged | 13D | Arcutis Biotherapeutics, Inc. ARQT | Frazier Life Sciences VIII L.P. | 10,542,790 24.1% | 0 (Unchanged) | View |
| 2020-07-30 8:16 pm Purchase | 13D | Alpine Immune Sciences, Inc. ALPN | Frazier Life Sciences VIII L.P. | 2,737,101 11.5% | 11,475 (+0.42%) | View |
| 2020-06-18 12:30 pm Sale | 13D | ENTASIS THERAPEUTICS HOLDINGS INC. ETTX | Frazier Life Sciences VIII L.P. | 799,953 2.9% | -250,000 (-23.81%) | View |
| 2020-04-29 4:46 pm Sale | 13D | Sierra Oncology Inc. SRRA | Frazier Life Sciences VIII L.P. | 202,803 2% | -7,909,318 (-97.50%) | View |
| 2020-03-23 4:07 pm Sale | 13D | ENTASIS THERAPEUTICS HOLDINGS INC. ETTX | Frazier Life Sciences VIII L.P. | 1,049,953 7.9% | -250,000 (-19.23%) | View |
| 2020-02-07 4:04 pm Purchase | 13D | Arcutis Biotherapeutics, Inc. ARQT | Frazier Life Sciences VIII L.P. | 10,542,790 27.7% | 10,542,790 (New Position) | View |
| 2020-01-16 1:19 pm Purchase | 13D | Aptinyx Inc. APTX | Frazier Life Sciences VIII L.P. | 3,240,116 7.1% | 50,037 (+1.57%) | View |
| 2020-01-13 10:35 am Sale | 13D | ENTASIS THERAPEUTICS HOLDINGS INC. ETTX | Frazier Life Sciences VIII L.P. | 1,299,953 9.8% | -50,000 (-3.70%) | View |
| 2019-01-22 6:10 pm Purchase | 13D | Alpine Immune Sciences, Inc. ALPN | Frazier Life Sciences VIII L.P. | 2,725,626 14.6% | 526,615 (+23.95%) | View |
| 2018-11-13 5:35 pm Purchase | 13D | Sierra Oncology Inc. DNAI | Frazier Life Sciences VIII L.P. | 8,112,121 10.9% | 8,112,121 (New Position) | View |
| 2018-10-09 06:10 am Purchase | 13D | ENTASIS THERAPEUTICS HOLDINGS INC. ETTX | Frazier Life Sciences VIII L.P. | 1,349,953 10.3% | 1,349,953 (New Position) | View |
| 2018-07-03 5:42 pm Purchase | 13D | Aptinyx Inc. APTX | Frazier Life Sciences VIII L.P. | 3,190,079 9.5% | 3,190,079 (New Position) | View |